Poland· PL-100532810
Inluriyo
A medicinal product containing imlunestrant, registered in Poland by Eli Lilly Nederland B.V..
Checked against URPL (Poland) on
Informational only — not a medical device.
The record
At a glance
URPL (Poland)- Active substance
- Imlunestrant
- Manufacturer
- Eli Lilly Nederland B.V.
- Country
- Poland (PL)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Imlunestrant in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaINLURIYOEli Lilly Nederland B.V., Utrecht
- SwitzerlandInluriyo 200 mg, comprimés pelliculésEli Lilly (Suisse) SA
- United StatesInluriyoEli Lilly and Company
- BelgiumInluriyo 200 mgEli Lilly Nederland
- IcelandInluriyoEli Lilly Nederland B.V.*
- NetherlandsInluriyo 200 mg filmomhulde tablettenEli Lilly Nederland B.V.
- SwedenInluriyo 200 mg Filmdragerad tablettEli Lilly Nederland B.V.
- IrelandInluriyo 200 mg film-coated tabletsEli Lilly and Company Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Inluriyo
- Liechtenstein · Inluriyo
- Norway · Inluriyo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a948b384-c24a-402b-8f84-ac074fede0ee GET /v1/drugs/a948b384-c24a-402b-8f84-ac074fede0ee?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "200 mg",
"packaging": "Rpz ¦ EU/1/25/2003/001 ¦ 165742\n14 tabl.\nRpz ¦ EU/1/25/2003/002 ¦ 165743\n28 tabl.\nRpz ¦ EU/1/25/2003/003 ¦ 165744\n42 tabl.\nRpz ¦ EU/1/25/2003/004 ¦ 165745\n56 tabl.\nRpz ¦ EU/1/25/2003/005 ¦ 165746\n70 tabl.\nRpz ¦ EU/1/25/2003/006 ¦ 165747\n168 tabl.",
"substance": "Imlunestrant 200 mg",
"common_name": "Imlunestrant",
"pl_product_id": "100532810",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about imlunestrant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.